Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von CandyButcher 

Intra-Cellular Therapies Inc. diskutieren

Intra-Cellular Therapies Inc.

WKN: A1XDTL / Symbol: ITCI / Name: ITI / Aktie / Biotechnologie & medizinische Forschung / Small Cap /

67,50 €
0,00 %

Einschätzung Buy
Rendite (%) 4,17 %
Kursziel 93,28
Veränderung
Endet am 23.02.25

Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $101.00 price target on the stock.
Ratings data for ITCI provided by MarketBeat

Einschätzung Buy
Rendite (%) 8,00 %
Kursziel 79,68
Veränderung
Endet am 03.04.25

Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $86.00 price target on the stock.
Ratings data for ITCI provided by MarketBeat

Einschätzung Buy
Rendite (%) 5,47 %
Kursziel 75,83
Veränderung
Endet am 05.04.25

Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $82.00 price target on the stock.
Ratings data for ITCI provided by MarketBeat

Einschätzung Buy
Rendite (%) -1,46 %
Kursziel 84,35
Veränderung
Endet am 18.04.25

Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its price target raised by analysts at TD Cowen from $80.00 to $90.00. They now have a "buy" rating on the stock.
Ratings data for ITCI provided by MarketBeat

Einschätzung Buy
Rendite (%) -1,46 %
Kursziel 96,53
Veränderung
Endet am 18.04.25

Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its price target raised by analysts at Robert W. Baird from $83.00 to $103.00. They now have an "outperform" rating on the stock.
Ratings data for ITCI provided by MarketBeat

Einschätzung Buy
Rendite (%) -1,46 %
Kursziel 85,29
Veränderung
Endet am 18.04.25

Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its price target raised by analysts at Bank of America Co. from $82.00 to $91.00. They now have a "buy" rating on the stock.
Ratings data for ITCI provided by MarketBeat

Einschätzung Buy
Rendite (%) -4,26 %
Kursziel 90,20
Veränderung
Endet am 22.04.25

Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its price target raised by analysts at Mizuho from $82.00 to $96.00. They now have a "buy" rating on the stock.
Ratings data for ITCI provided by MarketBeat

Einschätzung Buy
Rendite (%) -4,26 %
Kursziel 84,46
Veränderung
Endet am 22.04.25

Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its price target raised by analysts at Needham & Company LLC from $82.00 to $90.00. They now have a "buy" rating on the stock.
Ratings data for ITCI provided by MarketBeat

Einschätzung Buy
Rendite (%) -1,46 %
Kursziel 112,30
Veränderung
Endet am 24.04.25

Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $120.00 price target on the stock.
Ratings data for ITCI provided by MarketBeat